Evidence map›Paper›PMID 25069980›Full record

ArticleInfection and immunity2014

Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Marina N Matos, Silvia I Cazorla, Augusto E Bivona, Celina Morales, Carlos A Guzmán, Emilio L Malchiodi

Abstract read
In one paragraph

Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Use ofFrontiers in microbiology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marina N MatosCátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral, UBA-CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina Instituto de Microbiología y Parasitología Médica, UBA-CONICET, and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Silvia I CazorlaCátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral, UBA-CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina Instituto de Microbiología y Parasitología Médica, UBA-CONICET, and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Augusto E BivonaCátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral, UBA-CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina Instituto de Microbiología y Parasitología Médica, UBA-CONICET, and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Celina MoralesInstituto de Fisiopatología Cardiovascular, Departamento de Patología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Carlos A GuzmánDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Emilio L MalchiodiCátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral, UBA-CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina Instituto de Microbiología y Parasitología Médica, UBA-CONICET, and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina emalchio@ffyb.uba.ar.

Funding

Structure and Function of Natural Killer Cell ReceptorsR03TW007972 · FIC · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI MARIUZZA, ROY A · 2007 to 2008
$77k
FIC NIH HHS R03 TW007972FIC NIH HHS TW007972
6 · The paper itself

Abstract

In this work we immunized mice with DNA encoding full-length Tc52 or its amino- or carboxy-terminal (N- and C-term, respectively) domain carried by attenuated Salmonella as a DNA delivery system. As expected, Salmonella-mediated DNA delivery resulted in low antibody titers and a predominantly Th1 response, as shown by the ratio of IgG2a/IgG1-specific antibodies. Despite modest expression of Tc52 in trypomastigotes, the antibodies elicited by vaccination were able to mediate lysis of the trypomastigotes in the presence of complement and inhibit their invasion of mammal cells in vitro. The strongest functional activity was observed with sera from mice immunized with Salmonella carrying the N-term domain (SN-term), followed by Tc52 (STc52), and the C-term domain (SC-term). All immunized groups developed strong cellular responses, with predominant activation of Th1 cells. However, mice immunized with SN-term showed higher levels of interleukin-10 (IL-10), counterbalancing the inflammatory reaction, and also strong activation of Tc52-specific gamma interferon-positive (IFN-γ(+)) CD8(+) T cells. In agreement with this, although all prototypes conferred protection against infection, immunization with SN-term promoted greater protection than that with SC-term for all parameters tested and slightly better protection than that with STc52, especially in the acute stage of infection. We conclude that the N-terminal domain of Tc52 is the section of the protein that confers maximal protection against infection and propose it as a promising candidate for vaccine development.

Indexed as

Drug CarriersGenetic VectorsAnimalsAntibodies, ProtozoanCD8-Positive T-LymphocytesChagas DiseaseCytokinesDisease Models, AnimalFemaleImmunoglobulin GMiceMice, Inbred C3HMolecular Sequence DataProtozoan ProteinsProtozoan VaccinesRecombinant Proteins52-kDa protein, Trypanosoma cruziAntibodies, ProtozoanCytokinesDrug CarriersImmunoglobulin GProtozoan ProteinsProtozoan VaccinesRecombinant Proteins

Identifiers

PMID25069980
PMCPMC4187887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.